Description
Leqvio (inclisiran) is a prescription medication used to lower low-density lipoprotein cholesterol (LDL-C) levels in adults with hypercholesterolemia or mixed dyslipidemia. It is a small-interfering RNA (siRNA) drug that targets PCSK9, a protein that regulates LDL-C levels in the blood. By reducing the production of PCSK9, Leqvio can lower LDL-C levels and reduce the risk of cardiovascular events.
Uses:
Leqvio is used to lower low-density lipoprotein cholesterol (LDL-C) levels in adults with hypercholesterolemia or mixed dyslipidemia.
Storage Conditions:
Leqvio should be stored in the refrigerator at 36°F to 46°F (2°C to 8°C) until the expiration date. It should be protected from light and should not be frozen.
Mechanism of Action:
Leqvio (inclisiran) is a small-interfering RNA (siRNA) drug that targets PCSK9, a protein that regulates LDL-C levels in the blood. By reducing the production of PCSK9, Leqvio can lower LDL-C levels and reduce the risk of cardiovascular events.
HOW TO USE:
Leqvio is administered as a subcutaneous injection by a healthcare provider. The recommended dosage is 300 mg every six months. The injection should be given in the stomach, thigh, or upper arm. Patients should receive an injection at baseline, at three months, and then every six months thereafter.
Precautions:
• Patients should inform their healthcare provider if they have liver or kidney problems, bleeding disorders, or are pregnant or planning to become pregnant.
• Leqvio may increase the risk of bleeding. Patients taking Leqvio should be monitored for signs of bleeding and advised to avoid certain activities, such as excessive alcohol consumption or heavy lifting.
• Leqvio may interact with other medications, including warfarin and other blood thinners. Patients should inform their healthcare provider of all medications they are taking before starting Leqvio.
Drug Interactions:
• Leqvio may interact with other medications, including warfarin and other blood thinners.
• Patients should inform their healthcare provider of all medications they are taking before starting Leqvio.
Contraindications:
• Leqvio should not be used in patients with a known hypersensitivity to the medication or its components.
• It is not recommended for use in patients with active liver disease or unexplained persistent elevations of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels.
Overdose:
There is limited information on the overdose of Leqvio. However, patients who experience an overdose of Leqvio should seek immediate medical attention.
Adverse Reactions:
The most common adverse reactions experienced by patients taking Leqvio include injections site reactions, such as pain, redness, or swelling. Other potential side effects include itching, rash, and muscle pain. Patients should contact their healthcare provider if they experience any unusual symptoms while taking Leqvio.
In conclusion, Leqvio (inclisiran) is a small-interfering RNA (siRNA) drug that reduces PCSK9 production and lowers LDL-C levels in adults with hypercholesterolemia or mixed dyslipidemia. The recommended dosage is 300 mg administered as a subcutaneous injection every six months. Before taking Leqvio, patients should inform their healthcare provider of any liver or kidney problems, bleeding disorders, or pregnancy. Adverse reactions may include injection site reactions, itching, and muscle pain. Leqvio should not be used by those with hypersensitivity to the medication or its components, active liver disease, or unexplained persistent elevations of ALT or AST levels. Leqvio may interact with other medications, including warfarin and other blood thinners.
Reviews
There are no reviews yet.